PL3953357T3 - Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRA - Google Patents
Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRAInfo
- Publication number
- PL3953357T3 PL3953357T3 PL20721083.2T PL20721083T PL3953357T3 PL 3953357 T3 PL3953357 T3 PL 3953357T3 PL 20721083 T PL20721083 T PL 20721083T PL 3953357 T3 PL3953357 T3 PL 3953357T3
- Authority
- PL
- Poland
- Prior art keywords
- pdgfra
- mediated diseases
- pyrrolotriazine derivatives
- treating kit
- kit
- Prior art date
Links
- 101150038994 PDGFRA gene Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833529P | 2019-04-12 | 2019-04-12 | |
| US201962911016P | 2019-10-04 | 2019-10-04 | |
| US201962930240P | 2019-11-04 | 2019-11-04 | |
| PCT/US2020/027177 WO2020210293A1 (en) | 2019-04-12 | 2020-04-08 | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3953357T3 true PL3953357T3 (pl) | 2024-09-02 |
Family
ID=70416596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20721083.2T PL3953357T3 (pl) | 2019-04-12 | 2020-04-08 | Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRA |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20220153748A1 (pl) |
| EP (2) | EP3953357B1 (pl) |
| JP (2) | JP7600140B2 (pl) |
| KR (1) | KR102875260B1 (pl) |
| CN (1) | CN113939515B (pl) |
| AU (1) | AU2020272743B2 (pl) |
| BR (1) | BR112021020441A2 (pl) |
| CA (1) | CA3136802A1 (pl) |
| CL (1) | CL2021002656A1 (pl) |
| CO (1) | CO2021015113A2 (pl) |
| DK (1) | DK3953357T3 (pl) |
| EC (1) | ECSP21080096A (pl) |
| ES (1) | ES2980811T3 (pl) |
| FI (1) | FI3953357T3 (pl) |
| HR (1) | HRP20240702T1 (pl) |
| HU (1) | HUE067299T2 (pl) |
| IL (1) | IL287168B2 (pl) |
| LT (1) | LT3953357T (pl) |
| MA (1) | MA55604B1 (pl) |
| MD (1) | MD3953357T2 (pl) |
| MX (1) | MX2021012469A (pl) |
| MY (1) | MY209048A (pl) |
| PE (1) | PE20212331A1 (pl) |
| PH (1) | PH12021552568A1 (pl) |
| PL (1) | PL3953357T3 (pl) |
| PT (1) | PT3953357T (pl) |
| RS (1) | RS65644B1 (pl) |
| SG (1) | SG11202111244XA (pl) |
| SI (1) | SI3953357T1 (pl) |
| SM (1) | SMT202400229T1 (pl) |
| TW (1) | TWI857043B (pl) |
| WO (1) | WO2020210293A1 (pl) |
| ZA (1) | ZA202108104B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109970745B (zh) | 2018-04-16 | 2020-12-08 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
| KR102875260B1 (ko) * | 2019-04-12 | 2025-10-23 | 블루프린트 메디신즈 코포레이션 | Kit- 및 pdgfra 매개성 질환을 치료하기 위한 피롤로트리아진 유도체 |
| WO2022081626A1 (en) * | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
| CN117098760A (zh) * | 2020-10-14 | 2023-11-21 | 缆图药品公司 | 用于治疗kit和pdgfra介导的疾病的组合物和方法 |
| HU231413B1 (hu) | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Eljárás avapritinib és intermedierek előállítására |
| IL305611A (en) * | 2021-03-03 | 2023-11-01 | Blueprint Medicines Corp | Synthetic methods and intermediates for the production of compounds for the treatment of PDGFRA-mediated diseases and kits |
| CA3211477A1 (en) | 2021-03-10 | 2022-09-15 | Caitlin KINKEMA | Salt and solid forms of a kinase inhibitor |
| CN113278023B (zh) * | 2021-07-22 | 2021-10-15 | 上海睿跃生物科技有限公司 | 含氮杂环化合物及其制备方法和应用 |
| IL312506A (en) * | 2021-11-08 | 2024-07-01 | Progentos Therapeutics Inc | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2024171143A1 (en) | 2023-02-17 | 2024-08-22 | Assia Chemical Industries Ltd. | Salts and solid forms of elenestinib |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (ja) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| CA2373990C (en) * | 1999-05-21 | 2007-05-08 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| ATE396978T1 (de) | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| PT1497019E (pt) | 2002-04-23 | 2015-09-10 | Bristol Myers Squibb Co | Compostos de pirrolotriazina anilina úteis como inibidores de quinase |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| NZ541836A (en) | 2003-02-27 | 2008-12-24 | Palau Pharma Sa | Pyrazolopyridine derivatives |
| US8076338B2 (en) | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2006028524A2 (en) | 2004-04-29 | 2006-03-16 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CA2636701C (en) | 2006-01-27 | 2014-08-05 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors |
| JP5185930B2 (ja) | 2006-07-07 | 2013-04-17 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| AU2008279097B2 (en) | 2007-07-25 | 2013-05-02 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| EP2288611B1 (en) | 2008-03-20 | 2013-05-15 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| CN102573486A (zh) | 2009-06-08 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| CA2987503C (en) | 2009-07-07 | 2019-02-26 | Mei Pharma, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| EP2536689A1 (en) | 2010-02-17 | 2012-12-26 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (zh) | 2010-11-12 | 2011-05-04 | 西北师范大学 | 对氟苯甲醛的制备方法 |
| CN104981247A (zh) | 2012-09-06 | 2015-10-14 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
| US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| SG11201602937UA (en) | 2013-10-17 | 2016-05-30 | Blueprint Medicines Corp | Compositions useful for treating disorders related to kit |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| WO2018183712A1 (en) * | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109400610A (zh) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途 |
| CN108191874B (zh) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| TW202039862A (zh) | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | 受體酪氨酸激酶(kit)基因突變 |
| KR102875260B1 (ko) * | 2019-04-12 | 2025-10-23 | 블루프린트 메디신즈 코포레이션 | Kit- 및 pdgfra 매개성 질환을 치료하기 위한 피롤로트리아진 유도체 |
| CN110950872A (zh) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
| CN110938077B (zh) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
-
2020
- 2020-04-08 KR KR1020217036868A patent/KR102875260B1/ko active Active
- 2020-04-08 ES ES20721083T patent/ES2980811T3/es active Active
- 2020-04-08 FI FIEP20721083.2T patent/FI3953357T3/fi active
- 2020-04-08 BR BR112021020441A patent/BR112021020441A2/pt unknown
- 2020-04-08 WO PCT/US2020/027177 patent/WO2020210293A1/en not_active Ceased
- 2020-04-08 US US17/602,770 patent/US20220153748A1/en active Pending
- 2020-04-08 RS RS20240664A patent/RS65644B1/sr unknown
- 2020-04-08 HU HUE20721083A patent/HUE067299T2/hu unknown
- 2020-04-08 SG SG11202111244XA patent/SG11202111244XA/en unknown
- 2020-04-08 MX MX2021012469A patent/MX2021012469A/es unknown
- 2020-04-08 EP EP20721083.2A patent/EP3953357B1/en active Active
- 2020-04-08 PE PE2021001699A patent/PE20212331A1/es unknown
- 2020-04-08 MA MA55604A patent/MA55604B1/fr unknown
- 2020-04-08 PT PT207210832T patent/PT3953357T/pt unknown
- 2020-04-08 DK DK20721083.2T patent/DK3953357T3/da active
- 2020-04-08 AU AU2020272743A patent/AU2020272743B2/en active Active
- 2020-04-08 EP EP24170331.3A patent/EP4424312A3/en active Pending
- 2020-04-08 SI SI202030454T patent/SI3953357T1/sl unknown
- 2020-04-08 HR HRP20240702TT patent/HRP20240702T1/hr unknown
- 2020-04-08 CA CA3136802A patent/CA3136802A1/en active Pending
- 2020-04-08 US US16/842,969 patent/US10829493B2/en active Active
- 2020-04-08 LT LTEPPCT/US2020/027177T patent/LT3953357T/lt unknown
- 2020-04-08 SM SM20240229T patent/SMT202400229T1/it unknown
- 2020-04-08 TW TW109111858A patent/TWI857043B/zh active
- 2020-04-08 MD MDE20220189T patent/MD3953357T2/ro unknown
- 2020-04-08 IL IL287168A patent/IL287168B2/en unknown
- 2020-04-08 PL PL20721083.2T patent/PL3953357T3/pl unknown
- 2020-04-08 CN CN202080042732.0A patent/CN113939515B/zh active Active
- 2020-04-08 JP JP2021560255A patent/JP7600140B2/ja active Active
- 2020-04-08 MY MYPI2021006079A patent/MY209048A/en unknown
-
2021
- 2021-04-08 PH PH1/2021/552568A patent/PH12021552568A1/en unknown
- 2021-10-12 CL CL2021002656A patent/CL2021002656A1/es unknown
- 2021-10-21 ZA ZA2021/08104A patent/ZA202108104B/en unknown
- 2021-11-09 CO CONC2021/0015113A patent/CO2021015113A2/es unknown
- 2021-11-12 EC ECSENADI202180096A patent/ECSP21080096A/es unknown
-
2024
- 2024-12-03 JP JP2024210028A patent/JP2025029094A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287168A (en) | Kit of pyrrolotriazine derivatives for the treatment of diseases mediated by pdgfra | |
| IL277190A (en) | Methods of treating HPV-related diseases | |
| IL277333A (en) | Methods for treating eye diseases | |
| LT3728271T (lt) | Makrocikliniai junginiai, skirti ligų gydymui | |
| IL287907A (en) | Cancer treatment methods | |
| IL291735A (en) | Heteroarylbiphenylamines for the treatment of pd-l1 diseases | |
| SG11202112800SA (en) | Illumination for photodynamic therapy | |
| IL323370A (en) | Development of indazolyl-isoxazole for cancer treatment | |
| EP4034128A4 (en) | TUMOR REGRESSION INDUCTION METHOD | |
| IL291565A (en) | A method for treating phenylalanine irregularity | |
| IL276639A (en) | Materials and methods for the treatment of dysproliferative diseases | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| GB201908885D0 (en) | Therapeutic compounds | |
| SG11202110659SA (en) | Method for treating ocular diseases | |
| IL289436A (en) | Methods for treating eye diseases | |
| EP4058063A4 (en) | METHODS OF TREATMENT OF DISEASES | |
| GB201909466D0 (en) | Compounds for treating cancer | |
| HK40076432A (en) | Compounds and methods for treating oxalate-related diseases | |
| HK40123763A (zh) | 适用於治疗心血管疾病的新型化合物 | |
| HK40072711A (en) | Dosing regimens for treating or preventing c5-associated diseases | |
| HK40078516A (zh) | 诱导肿瘤消退的方法 | |
| HK40067840A (en) | Methods for treating ocular diseases | |
| HK40058903A (en) | Therapeutic methods for treating hepatitis b | |
| GB201911574D0 (en) | Therapeutic compounds |